December 2020

Current and emerging indications for use in ovarian, breast, pancreatic, and prostate cancers are presented.

A shift toward precision oncology has individual treatment plans being created for improving patient outcomes.

In contrast with standard chemotherapy, long-term follow-up with ICI therapies showed a long-lasting effect on overall survival for non−small cell lung cancer.

The SUNY Outpatient Pharmacy has developed a strong collaboration with specialty pharmacy personnel and clinically embedded pharmacists.

HER2+ breast cancer accounts for 15% to 30% of the 276,480 women diagnosed with breast cancer annually in the United States.

Specialty pharmacies are the primary provider of oncology-related medication therapy.

In the 2020 Directions in Oncology Pharmacy® conference session, redefining the management of anemia in patients with cancer was discussed.

Pharmacists’ Roles in Addressing Oncology Biosimilar Challenges

Experts say the COVID-19 pandemic may create a shortage of plasma therapy.

Pharmacists should communicate the universal message that colorectal cancer screenings save lives.

Symposium speakers discussed how CDK4/6 inhibitors are game changers in treatment of HR+/HER2- advanced breast cancer.

A panel of experts discusses alert systems, surface contamination, and PPE as methods for minimizing exposure to dispensing pharmacists.

Belantamab mafodotin-blmf (Blenrep; GlaxoSmithKline) is the first in its class anti-BCMA therapy to gain FDA approval.

With the explosion of new therapies for cancer, the role of the oncology pharmacist continues to expand.

Heading into the new year, we hope that pharmacists and pharmacy staff enjoy a happy and safe holiday season, and receive a well-deserved break after working especially hard in 2020.